Literature DB >> 9638867

Effect of isoleucine on toxin production by Clostridium difficile in a defined medium.

D Ikeda1, T Karasawa, K Yamakawa, R Tanaka, M Namiki, S Nakamura.   

Abstract

Supplementation of a carbohydrate-free minimal medium with a high level (100 mM) of histidine, methionine, valine, isoleucine, proline and leucine, in particular isoleucine, markedly increased toxin production by Clostridium difficile VPI 10463. The effect of isoleucine was further examined. Increasing the concentration of isoleucine from 20 to 100 mM remarkably increased toxin production, while bacterial growth decreased gradually. Amino acid analysis of the culture revealed that, at 100 mM isoleucine, consumption of isoleucine was remarkably increased. During the incubation period when toxin titers increased markedly but bacterial growth was declining, isoleucine, leucine and cysteine were taken up preferentially and alanine and cystathionine, which were not found at 1 mM isoleucine, were produced in large quantities. These findings suggest that isoleucine may play an important role in toxin production by C. difficile and that alanine and cystathionine production may be co-regulated with the toxin production in the absence of fermentable carbohydrates.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9638867     DOI: 10.1016/s0934-8840(98)80174-6

Source DB:  PubMed          Journal:  Zentralbl Bakteriol        ISSN: 0934-8840


  11 in total

1.  Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor.

Authors:  N Mani; B Dupuy
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

Review 2.  Interactions Between the Gastrointestinal Microbiome and Clostridium difficile.

Authors:  Casey M Theriot; Vincent B Young
Journal:  Annu Rev Microbiol       Date:  2015       Impact factor: 15.500

3.  Analysis of proline reduction in the nosocomial pathogen Clostridium difficile.

Authors:  Sarah Jackson; Mary Calos; Andrew Myers; William T Self
Journal:  J Bacteriol       Date:  2006-10-13       Impact factor: 3.490

Review 4.  Microbial and metabolic interactions between the gastrointestinal tract and Clostridium difficile infection.

Authors:  Casey M Theriot; Vincent B Young
Journal:  Gut Microbes       Date:  2013-12-11

Review 5.  Integration of metabolism and virulence in Clostridium difficile.

Authors:  Laurent Bouillaut; Thomas Dubois; Abraham L Sonenshein; Bruno Dupuy
Journal:  Res Microbiol       Date:  2014-10-15       Impact factor: 3.992

6.  Environmental response and autoregulation of Clostridium difficile TxeR, a sigma factor for toxin gene expression.

Authors:  Nagraj Mani; Dena Lyras; Lisa Barroso; Pauline Howarth; Tracy Wilkins; Julian I Rood; Abraham L Sonenshein; Bruno Dupuy
Journal:  J Bacteriol       Date:  2002-11       Impact factor: 3.490

7.  d-Proline Reductase Underlies Proline-Dependent Growth of Clostridioides difficile.

Authors:  Michael A Johnstone; William T Self
Journal:  J Bacteriol       Date:  2022-07-13       Impact factor: 3.476

8.  The relationship between phenotype, ribotype, and clinical disease in human Clostridium difficile isolates.

Authors:  Paul E Carlson; Seth T Walk; Alexandra E T Bourgis; Melissa W Liu; Fatos Kopliku; Eugene Lo; Vincent B Young; David M Aronoff; Philip C Hanna
Journal:  Anaerobe       Date:  2013-04-20       Impact factor: 3.331

9.  Defined Nutrient Diets Alter Susceptibility to Clostridium difficile Associated Disease in a Murine Model.

Authors:  John H Moore; Caio C D Pinheiro; Edna I Zaenker; David T Bolick; Glynis L Kolling; Edward van Opstal; Francisco J D Noronha; Pedro H Q S De Medeiros; Raphael S Rodriguez; Aldo A Lima; Richard L Guerrant; Cirle A Warren
Journal:  PLoS One       Date:  2015-07-16       Impact factor: 3.240

10.  Differential stress transcriptome landscape of historic and recently emerged hypervirulent strains of Clostridium difficile strains determined using RNA-seq.

Authors:  Joy Scaria; Chunhong Mao; Jenn-Wei Chen; Sean P McDonough; Bruno Sobral; Yung-Fu Chang
Journal:  PLoS One       Date:  2013-11-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.